Organization
Rajiv Gandhi Cancer Institute and Research Center
3 abstracts
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
MET exon 14 skipping in NSCLC: An unMET Indian need.Org: Rajiv Gandhi Cancer Institute and Research Center, Tata Memorial Hospital, Tata Memorial Centre,
Abstract
Increased NGS testing and real-world clinical usage of targeted therapy: All dressed up, nowhere to go.Org: Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India, Indiana University – Purdue University Indianapolis, Delhi State Cancer Institute,